AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04931407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A 12-week interdisciplinary complex intervention
Description: The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian.
Study NCT06201741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [131I]/[18F]/[68Ga]ZT-111
Description: \[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory fast screen
Description: Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: German Pain Inventory
Description: German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory
Description: Validated questionnaire for pain.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fatigue Severity and Disability Scale (FSS)
Description: Validated questionnaire for perceived fatigue
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quick Motor Function Test
Description: An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Handheld Dynamometry (HHD)
Description: To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute walk test (6MWT)
Description: It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure pain threshold
Description: For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonometer Assessment
Description: Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vital signs
Description: Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
Study NCT04907162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Borg Scale
Description: the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
Study NCT04903704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 1 Minute Sit to Stand Test
Description: Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
Study NCT04705987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine 0.5 mg/24h Treatment 8 weeks
Study NCT04705987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1c/24h Treatment 8 weeks
Study NCT06792071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behavior Therapy (RO DBT)
Description: The intervention is a psychological treatment using Radically Open Dialectical Behavior Therapy (RO-DBT), consisting of individual therapy and skills training in group for approximately 22 weeks. Additionally, a parent group consisting of four sessions will be included as an adaptation to the adolescent group.
Study NCT06791278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After-school childcare educators will participate in a professional development course on delivering pedagogical and child-friendly exercise sessions. The children will receive 1-2 weekly sessions of 45-60 minutes of child-friendly exercise during after-school childcare programs. Duration: 1 year.
Study NCT06516458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Camera Based Kinematic Analysis
Description: Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
Study NCT05381207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Oral Tablet
Description: Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
Study NCT06790771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Supplement
Description: Participants in this intervention receive approximately 10 grams of the supplement, containing 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. The supplement is consumed in powdered form after an 8-hour fasting period. Following a 60-minute rest, participants eat an ad libitum meal to assess the supplement's effect on hunger and food intake. Blood samples are collected at eight specific time points to measure metabolic markers, including GLP-1 levels, while hunger is tracked using a 7-point satiety scale. This intervention aims to determine the effects of a high dose of the supplement on appetite suppression and metabolic responses.
Study NCT06790771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Supplement
Description: In this intervention, participants consume approximately 5 grams of the supplement, which contains 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. The protocol mirrors that of the high-dose intervention: participants arrive after fasting for 8 hours, consume the supplement, rest for 60 minutes, and eat the standardized ad libitum meal. Blood samples are taken at the same eight time points to assess metabolic responses, and hunger levels are measured using the same satiety scale. This intervention investigates whether a lower dose of the supplement can still significantly affect hunger and GLP-1 secretion.
Study NCT06790771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention involves participants consuming a \~5 g inert powder with no active ingredients. Participants follow the same protocol as the other two interventions, including fasting, baseline blood collection, supplement (placebo) consumption, a 60-minute rest, and an ad libitum meal. Blood samples are collected at eight time points, and hunger levels are assessed with the 7-point scale. This intervention serves as a control, helping to determine whether observed effects in the other two interventions are attributable to the active supplement ingredients.
Study NCT06790511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioactive highly filled injectable flowable composite
Description: bioactive highly filled injectable flowable composite
Study NCT06790511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: highly filled injectable flowable composite
Description: highly filled injectable flowable composite
Study NCT06790498 — intervention group
Intervention type: BIOLOGICAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: No interventions in this trial
Study NCT06791798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator Hyperinflation
Description: In ventilator hyperinflation volume control mode, the ventilator will be set to eight breaths per minute, and the tidal volume will be increased to deliver hyperinflation breaths that are 15 ml/kg, as will be calculated using the predicted body weight. Tidal volume will be increased in 150-ml increments until a peak airway pressure of 40 cmH2O is achieved. Once this pressure is reached, eight mechanical breaths will be delivered to the patient. After this, the ventilator will be reset to pretreatment variables, and the patient will be rested for 30 s. The sequence will be repeated. The treatment will consist of five sets of eight ventilator hyperinflation breaths.
Study NCT06791798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibrocompression
Description: Vibrocompression will be performed by the physical therapist to produce vibration and will be combined with compression of the patient's chest in the expiratory phase. Every vibrocompression will be interrupted at the end of each expiratory phase to allow free inspiration.
Study NCT06791798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physical Therapy Program
Description: Percussion, Postural Drainage, and Suction
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifupinostat Hydrochloride for Injection
Description: Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Injection
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride for Injection
Description: Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin Injection
Description: Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide Injection
Description: Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide for Injection
Description: Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study NCT06792253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin Injection
Description: Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study NCT05715203 — intervention group
Intervention type: DEVICE
Intervention: Pulsotonometry
Description: Evaluation of arterial stiffness
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (for the first 8, 21-day, cycles)
Description: 1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (for the first 8, 21-day, cycles)
Description: 1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (for the first 8, 21-day, cycles)
Description: 25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (starting from cycle 9)
Description: 1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
Study NCT02556411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS 13,5 mg Levonorgestrel
Description: LNG-IUS
Study NCT02556411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS 13,5 mg Levonorgestrel
Description: LNG-IUS
Study NCT02556411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
Description: Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
Study NCT05539872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I004
Description: Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
Study NCT05539872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
Study NCT06501625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib Recommended Combination Dose (RCD)
Description: RCD administered orally once daily, taken continuously throughout treatment duration
Study NCT06234917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-based neurofeedback for brain activity modulation
Description: NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
Study NCT06234917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG-based neurofeedback for brain activity modulation
Description: NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
Study NCT06049238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization
Description: * Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Gatherings
Description: Participants in the social control group will have a social gathering at the participating center once weekly over the 16 weeks. They will also continue to receive the usual care offered by the centers, such as social support, and health education.
Study NCT06049238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post facilitation stretch
Description: * Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm-up Exercise
Description: Participants will perform mobilizing exercises of all upper and lower limb joints with music, and deep breathing exercises with music. This is a transitional phase that allows the body to adjust to the changing physiological, biomechanical, and bioenergetics demands placed on it during the conditioning or sports phase of the exercise session. Warming up also improves the range of movement and may reduce the risk of injury.
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Marching
Description: Participants are trained for their attention to the rhythm of music, and perform aerobic exercises. Participants are required to select and focus on the music elements to accomplish the mental tasks, i.e. moving the body parts accordingly and accurately. Rhythmic aerobic exercise of moderate intensity involving large muscle groups and requiring little skill is recommended for all adults to improve health and cardiorespiratory functioning. Even light- to moderate-intensity exercise may be beneficial in deconditioned individuals.
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing Familiar Songs
Description: Participants can rest for 5 minutes by singing before the next physical exercise training regime. They will listen to a familiar song regarded as cognitively stimulating because familiar music evokes autobiographical memory. Singing is more engaging than listening and brings additional benefits by synthesizing a range of specific speech, language, respiratory control, and vital capacity.
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Workout
Description: Participants are asked to remember steps and sequences demonstrated by the interventionist as memory training. The exercise comprises seated upper and lower extremity exercises. Elastic bands will be used to adjust the resistance intensity. The dance will be choreographed with the beat of selected and familiar music. The movement emphasizes rhythmic and contralateral movements on both sides of the body to enhance coordination and stimulation between the left and right cerebral hemispheres.
Study NCT06791720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise with Relaxing Music
Description: Participants will perform stretching exercises that can improve the range of movement in the major muscle and tendon groups. When stretching exercises following resistance training, postural stability, and balance can be improved.
Study NCT06177730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Hospital ECPR
Description: Implementation of pre-Hospital ECPr in OHCA
Study NCT06212388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded allogeneic γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
Study NCT06212388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ex-vivo expanded allogeneic γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
Study NCT06212388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1b
Description: Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
Study NCT06212388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.